Inivata Opens US CLIA Laboratory in Research Triangle Park

September 13, 2016

Research Triangle Park, NC; Cambridge, UK – September 12th, 2016 – Inivata, a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, formally announces the establishment of its US site in Research Triangle Park, NC (RTP) with an Open Laboratory reception and visit from Secretary of Commerce John E. Skvarla III. Inivata was founded in Cambridge, UK in September 2014, and draws on world-class research from the University of Cambridge and Cancer Research UK. The founders are pioneers in the field of ctDNA, having first utilized a simple blood draw, or ‘liquid biopsy’, to enable personalized cancer treatment in 2009. Inivata’s platform offers clinically actionable information for oncologists to improve cancer treatment and enable personalized medicine.
Michael Stocum, CEO of Inivata, said, “The Research Triangle Park is particularly alluring for launching our US operations as it has a unique blend of major academic medical centers, innovative biotech, information technology, biopharmaceutical and contract research organizations plus a fantastic quality of life. We are excited about the local scientific, clinical and bioinformatics talent pool as we continue attracting world class individuals to our team. We expect significant growth over the coming months as we aggressively expand our clinical development activities and commercialization plans to transform the lives of cancer patients through our innovative liquid biopsy offerings.”
“Inivata will be right at home in North Carolina, a state that embraces life science innovation and is an international leader in clinical trials and biomedical testing for personalized patient care,” said Commerce Secretary John Skvarla III. “We are eager to be part of this company’s cutting-edge treatment platform and global business strategy.”
According to statistics from the NC Biotechnology Center website life science jobs in NC are growing at more than three times the national average. North Carolina and the Research Triangle Park in particular, offers outstanding resources in bioscience mainly in research and testing which attracted Inivata to the area.
“The Biotech Center is delighted that we’ve been able to work with Michael Stocum and other members of the Inivata team, along with our public and private partners, to help bring this exciting new facility to North Carolina,” said Doug Edgeton, president and CEO of NCBiotech. “This is a great fit with our expanding push for statewide awareness and adoption of precision medicine. Adding this kind of Inivata innovation positions the state to be an even more formidable contender for life science business opportunities in this sector.”
Early this year Inivata completed a Series A round of approximately $45 million (£31.5 million), securing funds for clinical studies and validation of its technology platform for the analysis of ctDNA. Analytical validation, presented in April at AACR, showed its broad molecular profiling as a robust and reproducible method of detecting genomic alterations in ctDNA with best-in-class sensitivity and specificity. Inivata’s proprietary platform will be applied across a spectrum of solid tumors to provide oncologists with clinically actionable information to stratify patients, monitor treatment progress, and identify emerging tumor resistance.


Interviews available on request.

Photo of North Carolina Secretary of Commerce John E. Skvarla and Inivata CEO Michael Stocum

Contact details:
Liz Macfadyen
Phone: +44 (0)7739462323

Consilium Strategic Communications
Chris Gardner/Laura Thornton
Phone: +44 (0)20 3709 5700

About Inivata
Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s InVision® ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. For more information and a full listing of investors, please go to Follow us on Twitter @Inivata

Discover more news